Cargando…

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis

Given the high prevalence of multidrug-resistant (MDR)-TB in high HIV burden settings, it is important to identify potential drug-drug interactions between MDR-TB treatment and widely used nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-positive children. Population pharmacokinetic models...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Laan, Louvina E., Garcia-Prats, Anthony J., Schaaf, H. Simon, Winckler, Jana L., Draper, Heather, Norman, Jennifer, Wiesner, Lubbe, McIlleron, Helen, Denti, Paolo, Hesseling, Anneke C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531271/ https://www.ncbi.nlm.nih.gov/pubmed/34690765 http://dx.doi.org/10.3389/fphar.2021.722204

Ejemplares similares

Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children
por: van der Laan, Louvina E, et al.
Publicado: (2023)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies
por: Garcia-Prats, Anthony J., et al.
Publicado: (2019)

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
por: Ali, Ali Mohamed, et al.
Publicado: (2023)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
por: Tikiso, Tjokosela, et al.
Publicado: (2021)

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
por: Gafar, Fajri, et al.
Publicado: (2023)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications
por: Court, R., et al.
Publicado: (2018)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai
por: Chen, Yong, et al.
Publicado: (2016)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
por: Wasmann, Roeland E., et al.
Publicado: (2023)

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
por: Vaghela, Jitendra H., et al.
Publicado: (2018)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
por: Gupta, Amita, et al.
Publicado: (2019)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Aureolic Acid Group of Agents as Potential Antituberculosis Drugs
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
por: Loukman, Moreea, et al.
Publicado: (2023)

Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals
por: Lucas, Andrew, et al.
Publicado: (2015)

Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors
por: Pepper, Dominique J, et al.
Publicado: (2010)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
por: Gualano, Gina, et al.
Publicado: (2016)

Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity
por: Wang, Yu, et al.
Publicado: (2019)

Adverse drug reaction profile of daily regimen antituberculosis treatment
por: Sankar, K. N. Hari, et al.
Publicado: (2022)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jds9p32silqpvqm93lp6infqtc